Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Friday.
Several other equities research analysts also recently issued reports on RPRX. The Goldman Sachs Group boosted their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a "buy" rating in a report on Wednesday, August 14th. UBS Group downgraded Royalty Pharma from a "buy" rating to a "neutral" rating and set a $28.00 price objective on the stock. in a report on Monday, June 3rd. Finally, Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.00.
Get Our Latest Report on Royalty Pharma
Royalty Pharma Price Performance
Shares of NASDAQ:RPRX traded down $0.10 during midday trading on Friday, hitting $29.03. The company had a trading volume of 2,939,850 shares, compared to its average volume of 2,724,184. Royalty Pharma has a twelve month low of $25.20 and a twelve month high of $31.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. The stock has a market cap of $17.34 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 4.01 and a beta of 0.46. The business's 50-day simple moving average is $27.34 and its 200-day simple moving average is $28.22.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. The firm had revenue of $537.00 million during the quarter, compared to analysts' expectations of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter last year, the firm earned $0.85 earnings per share. On average, research analysts predict that Royalty Pharma will post 4.04 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Ballentine Partners LLC boosted its position in shares of Royalty Pharma by 3.3% during the 1st quarter. Ballentine Partners LLC now owns 12,541 shares of the biopharmaceutical company's stock worth $381,000 after acquiring an additional 406 shares in the last quarter. NEOS Investment Management LLC boosted its position in shares of Royalty Pharma by 5.0% during the 4th quarter. NEOS Investment Management LLC now owns 8,589 shares of the biopharmaceutical company's stock worth $241,000 after acquiring an additional 409 shares in the last quarter. Xponance Inc. boosted its position in shares of Royalty Pharma by 1.9% in the 2nd quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company's stock valued at $836,000 after purchasing an additional 606 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 655 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Royalty Pharma by 10.8% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company's stock valued at $276,000 after purchasing an additional 887 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Further Reading
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
